ArticleClinical kidney journal2026
Validation of biomarker-based stratification for risk of long-term outcomes after acute kidney injury.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Top ten tips to manage patients after acute kidney injury.Clinical kidney journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) is common and associated with adverse long-term outcomes. Previously we have shown that a four-biomarker model of soluble tumour necrosis factor receptor-1 and -2 (sTNFR1, sTNFR2), cystatin C and estimated glomerular filtration rate (eGFR) measured 90 days after AKI performed well in predicting subsequent kidney disease progression. However, external validation in independent cohorts is essential to move these findings towards clinical application. Methods: A prospective, observational cohort of adults with AKI within 72 h of onset was assembled. Participants had study visits at time of AKI, then 30, 60 and 90 days later for biomarker sampling. Outcomes were assessed at 1 year, including major adverse kidney events (MAKE365, a composite of >25% decline in eGFR from baseline, kidney replacement therapy or death) and kidney disease progression. Logistic regression models incorporating biomarker combinations were evaluated using area under the receiver operating characteristic curve (AUC). Results: From 122 participants recruited at time of AKI, 89 survived and had biomarker measurements available from outpatient study visits. Of these, 35% developed MAKE365 and 30% had kidney disease progression at 1 year. The biomarker model (sTNFR1, sTNFR2, cystatin C, eGFR) measured at Day 90 discriminated those with MAKE365 with an AUC of 0.79 [95% confidence interval (CI) 0.68-0.91], and kidney disease progression with AUC 0.79 (95% CI 0.67-0.91). The biomarker model had comparable performance at earlier timepoints of Day 30 and 60. Conclusions: A biomarker panel comprising sTNFR1, sTNFR2, cystatin C and eGFR reliably predicts adverse outcomes up to 1 year post-AKI. This provides external validation of findings from previous biomarker discovery studies, and shows how this biomarker combination could be used to identify patients at lowest risk. This may support biomarker-guided approaches for personalized post-AKI risk stratification and follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.